Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194745 | 0.84 | MAPT (0.53) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL12706368 | 0.83 | MAPT (0.56) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3663503 | 0.82 | MAPT (0.51) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL19341771 | 0.81 | MAPT (0.51) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3933822 | 0.79 | FBP1 (0.49) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL264869 | 0.79 | FBP1 (0.49) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL265540 | 0.79 | FBP1 (0.52) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3933827 | 0.78 | FBP1 (0.48) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL195598 | 0.78 | P2RY12 (0.53) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL28079459 | 0.78 | PSEN1 (0.52) | MAPTFBP1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258805-A1 | INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2017-09-14 | — | — | US | disclosed |
| EP-2314593-B1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2314593-A1 | Platelet ADP receptor inhibitors | Portola Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | MAPT 4695/4885FBP1 658/4885KMT2A 4073/4885 |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | P2RX7, P2RY1, P2RY6 | MAPT 4142/4885FBP1 640/4885KMT2A 4377/4885 |
| US-20170258805-A1 | INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE | UGDH, GALE, UGGT1 | MAPT 1539/4885FBP1 96/4885KMT2A 652/4885 |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | MAPT 4729/4885FBP1 450/4885KMT2A 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.